Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

Inclusion Criteria: * Enrollment within 4 weeks following administration of the first Prolia® (denosumab 60 mg) injection * Received Prolia® subcutaneously for treatment of osteoporosis consistent with local (US/Canada) product label * Subject or subject's legally acceptable representative has provided informed consent. Exclusion Criteria: * Participation in ongoing or previous denosumab clinical trials * Currently enrolled in another investigational device or drug study, or less than 6 months since ending another investigational device or drug study(s), or receiving other investigational agent(s) * Contra-indicated for treatment with Prolia® according to the approved applicable local product label (US/Canada) * Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.